8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 3, 2026·SEC
Arbutus Biopharma Corporation(ABUS)Earnings, Financials & Key Ratios
ABUS•NASDAQ
$4.42
$851M mkt cap·Price updated May 6, 2026
AboutArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Show more
- Revenue$14M+128.2%
- EBITDA-$38M+49.1%
- Net Income-$34M+52.1%
- EPS (Diluted)-0.17+55.3%
- EBITDA Margin-270.96%+77.7%
- Operating Margin-270.96%+78.1%
- Net Margin-237.88%+79.0%
- ROE-38.52%+44.0%
- ROIC-47.06%+38.0%
- Debt/Equity0.01-26.4%
ABUS Key Insights
Arbutus Biopharma Corporation (ABUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 15.3%
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 11.1x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ABUS Price & Volume
Arbutus Biopharma Corporation (ABUS) stock price & volume — 10-year historical chart
Loading chart...
ABUS Growth Metrics
Arbutus Biopharma Corporation (ABUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-5.53%
5 Years15.29%
3 Years-28.8%
TTM128.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM52.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.97%
Return on Capital
10 Years-56.93%
5 Years-47.79%
3 Years-52.11%
Last Year-37.28%
ABUS Recent Earnings
Arbutus Biopharma Corporation (ABUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
Mar 23, 2026EPS
$0.01
Est $0.04
+71.5%
Revenue
$1M
Est $614,500
+71.0%
Q4 2025
Nov 13, 2025EPS
$0.04
Est $0.06
+28.6%
Revenue
$529,000
Est $841,000
-37.1%
Q3 2025
Aug 6, 2025EPS
$0.01
Est $0.02
+150.0%
Revenue
$11M
Est $2M
+575.0%
Q2 2025
May 14, 2025EPS
$0.13
Est $0.09
-44.4%
Revenue
$2M
Est $2M
-21.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 23, 2026 | $0.01vs $0.04+71.5% | $1Mvs $614,500+71.0% |
| Q4 2025 | Nov 13, 2025 | $0.04vs $0.06+28.6% | $529,000vs $841,000-37.1% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.02+150.0% | $11Mvs $2M+575.0% |
| Q2 2025 | May 14, 2025 | $0.13vs $0.09-44.4% | $2Mvs $2M-21.3% |
Based on last 12 quarters of dataView full earnings history →
ABUS Peer Comparison
Arbutus Biopharma Corporation (ABUS) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REPL | 272.34M | 3.42 | -1.11 | -149.55% | 0.18 | |||
 ASMB | 498.39M | 31.36 | -57.02 | 153.52% | -8.47% | -5.63% | 0.01 | |
 HBIO | 323.77M | 7.24 | -5.66 | -8.06% | -65.51% | -388.56% | 2.61 | |
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare ABUS vs Peers
Arbutus Biopharma Corporation (ABUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABUS Income Statement
Arbutus Biopharma Corporation (ABUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10.7M | 5.9M | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Revenue Growth % | 613.33% | -44.86% | 1.88% | 15.02% | 58.92% | 255.11% | -53.51% | -65.98% | 128.21% |
| Cost of Goods Sold | 62.7M | 57.9M | 57.6M | 47.48M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 585.98% | 981.36% | 958.26% | 686.74% | - | - | - | - | - |
| Gross Profit | -52M▲ 0% | -52M▲ 0.0% | -51.59M▲ 0.8% | -40.57M▲ 21.4% | 10.99M▲ 127.1% | 39.02M▲ 255.1% | 18.14M▼ 53.5% | 6.17M▼ 66.0% | 0▼ 100.0% |
| Gross Margin % | -485.98% | -881.36% | -858.26% | -586.74% | 100% | 100% | 100% | 100% | - |
| Gross Profit Growth % | 13.04% | 0% | 0.79% | 21.37% | 127.09% | 255.11% | -53.51% | -65.98% | -100% |
| Operating Expenses | 80.8M | 76.1M | 92.31M | 17.24M | 84.51M | 104.47M | 96.24M | 82.49M | 52.24M |
| OpEx % of Revenue | 755.14% | 1289.83% | 1535.7% | 249.33% | 769.11% | 267.75% | 530.53% | 1336.74% | 370.96% |
| Selling, General & Admin | 16.1M | 16M | 17.73M | 14.85M | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| SG&A % of Revenue | 150.47% | 271.19% | 294.91% | 214.71% | 155.95% | 45.71% | 123.89% | 358.26% | 112.85% |
| Research & Development | 62.7M | 57.9M | 57.6M | 49.34M | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| R&D % of Revenue | 585.98% | 981.36% | 958.26% | 713.6% | 596.12% | 216.33% | 406.26% | 875.66% | 179.23% |
| Other Operating Expenses | 2.2M | 7.3M | 16.98M | -46.94M | 1.87M | 2.23M | 69K | 6.34M | 11.11M |
| Operating Income | -110.9M▲ 0% | -89.8M▲ 19.0% | -143.9M▼ 60.2% | -57.81M▲ 59.8% | -73.52M▼ 27.2% | -65.46M▲ 11.0% | -78.1M▼ 19.3% | -76.32M▲ 2.3% | -38.16M▲ 50.0% |
| Operating Margin % | -1036.45% | -1522.03% | -2393.96% | -836.07% | -669.11% | -167.75% | -430.53% | -1236.74% | -270.96% |
| Operating Income Growth % | 77.44% | 19.03% | -60.25% | 59.83% | -27.19% | 10.97% | -19.32% | 2.28% | 50% |
| EBITDA | -108.87M | -87.62M | -141.87M | -55.83M | -71.77M | -64.03M | -76.7M | -74.94M | -38.16M |
| EBITDA Margin % | -1017.5% | -1485.07% | -2360.22% | -807.46% | -653.16% | -164.1% | -422.79% | -1214.37% | -270.96% |
| EBITDA Growth % | 77.8% | 19.52% | -61.92% | 60.65% | -28.55% | 10.78% | -19.79% | 2.29% | 49.08% |
| D&A (Non-Cash Add-back) | 2.03M | 2.18M | 2.03M | 1.98M | 1.75M | 1.43M | 1.4M | 1.38M | 0 |
| EBIT | -108.47M | -61.12M | -164.27M | -59.73M | -73.39M | -63.29M | -72.39M | -69.78M | 0 |
| Net Interest Income | 1.28M | 2.82M | 3K | -3.27M | -2.73M | 466K | 5.23M | 6.45M | 0 |
| Interest Income | 1.54M | 3M | 2.11M | 741K | 127K | 2.19M | 5.69M | 6.58M | 4.07M |
| Interest Expense | 261K | 200K | 2.11M | 4.01M | 2.86M | 1.73M | 459K | 137K | -97K |
| Other Income/Expense | 2.2M | 28.44M | -22.48M | -5.94M | -2.73M | 444K | 5.25M | 6.4M | 4.66M |
| Pretax Income | -108.7M▲ 0% | -61.4M▲ 43.5% | -166.38M▼ 171.0% | -63.74M▲ 61.7% | -76.25M▼ 19.6% | -65.01M▲ 14.7% | -72.85M▼ 12.1% | -69.92M▲ 4.0% | -33.5M▲ 52.1% |
| Pretax Margin % | -1015.89% | -1040.68% | -2767.91% | -921.97% | -693.91% | -166.62% | -401.57% | -1133.04% | -237.88% |
| Income Tax | -24.3M | -4.3M | -12.66M | 0 | 0 | 4.44M | 0 | 0 | 0 |
| Effective Tax Rate % | 22.36% | 7% | 7.61% | 0% | 0% | -6.84% | 0% | 0% | 0% |
| Net Income | -84.4M▲ 0% | -57.1M▲ 32.3% | -153.72M▼ 169.2% | -63.74M▲ 58.5% | -76.25M▼ 19.6% | -69.46M▲ 8.9% | -72.85M▼ 4.9% | -69.92M▲ 4.0% | -33.5M▲ 52.1% |
| Net Margin % | -788.79% | -967.8% | -2557.36% | -921.97% | -693.91% | -178.01% | -401.57% | -1133.04% | -237.88% |
| Net Income Growth % | 78.03% | 32.35% | -169.22% | 58.53% | -19.61% | 8.91% | -4.89% | 4.02% | 52.09% |
| Net Income (Continuing) | -84.41M | -57.06M | -153.72M | -63.74M | -76.25M | -69.46M | -72.85M | -69.92M | -33.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.54▲ 0% | -1.03▲ 33.1% | -2.69▼ 161.2% | -0.86▲ 68.0% | -0.73▲ 15.1% | -0.46▲ 37.0% | -0.44▲ 4.3% | -0.38▲ 13.6% | -0.17▲ 55.3% |
| EPS Growth % | 78.73% | 33.12% | -161.16% | 68.03% | 15.12% | 36.99% | 4.35% | 13.64% | 55.26% |
| EPS (Basic) | -1.54 | -1.03 | -2.69 | -0.86 | -0.73 | -0.46 | -0.44 | -0.38 | -0.17 |
| Diluted Shares Outstanding | 54.72M | 55.3M | 57.09M | 75.84M | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Basic Shares Outstanding | 54.69M | 55.3M | 57.09M | 75.84M | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ABUS Balance Sheet
Arbutus Biopharma Corporation (ABUS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 129.4M | 129.23M | 93.83M | 127.7M | 160.66M | 151.14M | 132.03M | 127.32M | 94.46M |
| Cash & Short-Term Investments | 126.4M | 124.62M | 90.83M | 123.27M | 155.32M | 146.91M | 126M | 122.62M | 91.47M |
| Cash Only | 54.3M | 36.94M | 31.8M | 52.25M | 109.28M | 30.78M | 26.29M | 36.33M | 18.01M |
| Short-Term Investments | 72.1M | 87.67M | 59.03M | 71.02M | 46.03M | 116.14M | 99.72M | 86.29M | 73.46M |
| Accounts Receivable | 870K | 1.43M | 1.2M | 1.31M | 899K | 1.35M | 1.78M | 2.41M | 1.45M |
| Days Sales Outstanding | 29.68 | 88.53 | 73.11 | 69.26 | 29.86 | 12.65 | 35.73 | 142.49 | 37.5 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 340K | 0 | 0 | 0 | 0 | 2.87M | 4.25M | 2.28M | 1.54M |
| Total Non-Current Assets | 107.8M | 98.68M | 11.71M | 9.38M | 43.82M | 44.28M | 12.37M | 4.39M | 162K |
| Property, Plant & Equipment | 12.2M | 10.14M | 11.41M | 9.33M | 8.07M | 6.81M | 6.09M | 4.36M | 32K |
| Fixed Asset Turnover | 0.88x | 0.58x | 0.53x | 0.74x | 1.36x | 5.73x | 2.98x | 1.42x | 440.09x |
| Goodwill | 24.4M | 22.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 58.6M | 43.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 12.6M | 22.22M | 0 | 0 | 35.69M | 37.36M | 6.28M | 0 | 0 |
| Other Non-Current Assets | 12.6M | 22.22M | 293K | 44K | 61K | 103K | 0 | 34K | 130K |
| Total Assets | 237.2M▲ 0% | 227.91M▼ 3.9% | 105.53M▼ 53.7% | 137.08M▲ 29.9% | 204.49M▲ 49.2% | 195.42M▼ 4.4% | 144.4M▼ 26.1% | 131.71M▼ 8.8% | 94.62M▼ 28.2% |
| Asset Turnover | 0.05x | 0.03x | 0.06x | 0.05x | 0.05x | 0.20x | 0.13x | 0.05x | 0.15x |
| Asset Growth % | -14.03% | -3.92% | -53.69% | 29.89% | 49.17% | -4.43% | -26.11% | -8.79% | -28.16% |
| Total Current Liabilities | 11.9M | 11.24M | 7.83M | 9.54M | 11.22M | 32.86M | 22.49M | 15.62M | 6.01M |
| Accounts Payable | 1.99M | 3.19M | 2.4M | 2.99M | 3.17M | 3.52M | 3.22M | 2.32M | 0 |
| Days Payables Outstanding | 11.57 | 20.12 | 15.2 | 23.02 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 372K | 0 | 0 | 547K |
| Deferred Revenue (Current) | 2.74M | 0 | 0 | 0 | 0 | 16.46M | 11.79M | 7.57M | 0 |
| Other Current Liabilities | 7M | 5.71M | 253K | 0 | 0 | 8.78M | 3.7M | 0 | 5.46M |
| Current Ratio | 10.87x | 11.50x | 11.99x | 13.38x | 14.32x | 4.60x | 5.87x | 8.15x | 15.73x |
| Quick Ratio | 10.87x | 11.50x | 11.99x | 13.38x | 14.32x | 4.60x | 5.87x | 8.15x | 15.73x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 42.8M | 16.43M | 24.96M | 25.57M | 23.82M | 25.71M | 15.9M | 18.72M | 12.04M |
| Long-Term Debt | 12M | 0 | 0 | 19.55M | 16.3M | 10.37M | 6.95M | 0 | 199K |
| Capital Lease Obligations | 0 | 0 | 3.02M | 2.59M | 2.23M | 1.81M | 1.34M | 806K | 0 |
| Deferred Tax Liabilities | 16.9M | 12.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 28.06M | 3.77M | 2.95M | 3.43M | 5.3M | 7.53M | 7.6M | 15.05M | 11.84M |
| Total Liabilities | 54.7M | 27.67M | 32.79M | 35.11M | 35.05M | 58.57M | 38.38M | 34.34M | 18.04M |
| Total Debt | 12M | 0 | 3.36M | 22.54M | 18.91M | 12.55M | 8.72M | 1.29M | 746K |
| Net Debt | -42.3M | -36.94M | -28.44M | -29.71M | -90.37M | -18.22M | -17.56M | -35.04M | -17.26M |
| Debt / Equity | 0.07x | - | 0.05x | 0.22x | 0.11x | 0.09x | 0.08x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -424.90x | -449.00x | -68.26x | -14.41x | -25.73x | -37.92x | -170.16x | -557.07x | - |
| Total Equity | 182.5M▲ 0% | 200.23M▲ 9.7% | 72.74M▼ 63.7% | 101.97M▲ 40.2% | 169.44M▲ 66.2% | 136.85M▼ 19.2% | 106.02M▼ 22.5% | 97.37M▼ 8.2% | 76.58M▼ 21.4% |
| Equity Growth % | -10.1% | 9.72% | -63.67% | 40.17% | 66.17% | -19.23% | -22.53% | -8.16% | -21.35% |
| Book Value per Share | 3.33 | 3.62 | 1.27 | 1.34 | 1.59 | 0.91 | 0.64 | 0.52 | 0.40 |
| Total Shareholders' Equity | 182.5M | 200.23M | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M | 97.37M | 76.58M |
| Common Stock | 876.11M | 879.4M | 898.53M | 985.94M | 1.29B | 1.32B | 1.35B | 1.41B | 0 |
| Retained Earnings | -738.07M | -805.22M | -970.09M | -1.05B | -1.13B | -1.2B | -1.28B | -1.35B | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -48.19M | -48.17M | -48.23M | -48.17M | -48.33M | -50.49M | -48.42M | -48.13M | -48.1M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABUS Cash Flow Statement
Arbutus Biopharma Corporation (ABUS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -48.6M | -67.9M | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M | -64.85M | -39.64M |
| Operating CF Margin % | -454.21% | -1150.85% | -1181.27% | -744.01% | -614.6% | -90.61% | -473.71% | -1050.88% | -281.45% |
| Operating CF Growth % | 16.04% | -39.71% | -4.57% | 27.55% | -31.28% | 47.65% | -143.06% | 24.54% | 38.88% |
| Net Income | -84.4M | -57.1M | -153.72M | -63.74M | -76.25M | -69.46M | -72.85M | -69.92M | -33.5M |
| Depreciation & Amortization | 2.03M | 2.18M | 2.03M | 1.98M | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Stock-Based Compensation | 15.12M | 6.24M | 6.8M | 6.16M | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Deferred Taxes | -24.32M | -4.28M | -12.66M | 0 | -8.18M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 39.83M | -10.66M | 88.78M | 3.73M | 7.79M | -3.75M | -5.56M | -2.47M | -13.45M |
| Working Capital Changes | 3.15M | -4.28M | -2.23M | 431K | 930K | 29.24M | -18.23M | -2.83M | 0 |
| Change in Receivables | -129K | -1.03M | 227K | -108K | 413K | -453K | -424K | -633K | 1.38M |
| Change in Inventory | -880K | 762K | 0 | 0 | -1.91M | 0 | 0 | 0 | 0 |
| Change in Payables | 736K | -1.27M | -2.41M | 1.67M | 1.91M | 5.22M | 0 | 0 | -2.1M |
| Cash from Investing | 27.8M | -4.1M | 28.34M | -14.91M | -12.68M | -74.94M | 50.77M | 22.95M | 15.58M |
| Capital Expenditures | -7.26M | -1.14M | -589K | -229K | -809K | -512K | -1.01M | -182K | 0 |
| CapEx % of Revenue | 67.89% | 19.29% | 9.8% | 3.31% | 7.36% | 1.31% | 5.56% | 2.95% | - |
| Acquisitions | 3K | 25K | 0 | -2.5M | 1.81M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 35.06M | -2.96M | 11K | 0 | -1.81M | 0 | 20K | 0 | 2.71M |
| Cash from Financing | 49.3M | 55.6M | 37.46M | 86.75M | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Debt Issued (Net) | 0 | -12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 48.87M | 66.27M | 18.6M | 86.3M | 134.66M | 20.32M | 29.85M | 44.12M | 0 |
| Dividends Paid | 0 | -10.09M | 0 | 0 | -12.14M | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 453K | 11.47M | 18.86M | 449K | 14.71M | 11.49M | 795K | 7.87M | 5.72M |
| Net Change in Cash | 30.9M▲ 0% | -17.4M▼ 156.3% | -5.14M▲ 70.4% | 20.45M▲ 497.7% | 57.03M▲ 178.9% | -78.51M▼ 237.7% | -4.49M▲ 94.3% | 10.04M▲ 323.7% | -18.32M▼ 282.4% |
| Free Cash Flow | -55.86M▲ 0% | -69.04M▼ 23.6% | -71.59M▼ 3.7% | -51.67M▲ 27.8% | -68.34M▼ 32.3% | -35.87M▲ 47.5% | -86.94M▼ 142.4% | -65.03M▲ 25.2% | -39.64M▲ 39.1% |
| FCF Margin % | -522.09% | -1170.14% | -1191.07% | -747.32% | -621.96% | -91.92% | -479.27% | -1053.83% | -281.45% |
| FCF Growth % | 9.72% | -23.58% | -3.7% | 27.83% | -32.26% | 47.52% | -142.4% | 25.2% | 39.05% |
| FCF per Share | -1.02 | -1.25 | -1.25 | -0.68 | -0.64 | -0.24 | -0.52 | -0.35 | -0.21 |
| FCF Conversion (FCF/Net Income) | 0.58x | 1.19x | 0.46x | 0.81x | 0.89x | 0.51x | 1.18x | 0.93x | 1.18x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABUS Key Ratios
Arbutus Biopharma Corporation (ABUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -102.33% | -43.79% | -29.84% | -112.63% | -72.97% | -56.19% | -45.35% | -59.99% | -68.76% | -38.52% |
| Return on Invested Capital (ROIC) | -128.8% | -50.14% | -44.38% | -103.98% | -74.39% | -72.88% | -49.66% | -56.57% | -75.92% | -47.06% |
| Gross Margin | -3986.67% | -485.98% | -881.36% | -858.26% | -586.74% | 100% | 100% | 100% | 100% | - |
| Net Margin | -25606.67% | -788.79% | -967.8% | -2557.36% | -921.97% | -693.91% | -178.01% | -401.57% | -1133.04% | -237.88% |
| Debt / Equity | 0.06x | 0.07x | - | 0.05x | 0.22x | 0.11x | 0.09x | 0.08x | 0.01x | 0.01x |
| Interest Coverage | - | -424.90x | -449.00x | -68.26x | -14.41x | -25.73x | -37.92x | -170.16x | -557.07x | - |
| FCF Conversion | 0.15x | 0.58x | 1.19x | 0.46x | 0.81x | 0.89x | 0.51x | 1.18x | 0.93x | 1.18x |
| Revenue Growth | -93.97% | 613.33% | -44.86% | 1.88% | 15.02% | 58.92% | 255.11% | -53.51% | -65.98% | 128.21% |
ABUS SEC Filings & Documents
Arbutus Biopharma Corporation (ABUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABUS Frequently Asked Questions
Arbutus Biopharma Corporation (ABUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arbutus Biopharma Corporation (ABUS) reported $14.1M in revenue for fiscal year 2025. This represents a 1047% increase from $1.2M in 1998.
Arbutus Biopharma Corporation (ABUS) grew revenue by 128.2% over the past year. This is strong growth.
Arbutus Biopharma Corporation (ABUS) reported a net loss of $33.5M for fiscal year 2025.
Dividend & Returns
Arbutus Biopharma Corporation (ABUS) has a return on equity (ROE) of -38.5%. Negative ROE indicates the company is unprofitable.
Arbutus Biopharma Corporation (ABUS) had negative free cash flow of $39.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More ABUS
Arbutus Biopharma Corporation (ABUS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates